Statement: In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia.
Primary_evidence: Adverse Events 1:   Total: 63/206 (30.58%)   Febrile neutropenia * 14/206 (6.80%)   Neutropenia * 9/206 (4.37%)   Anaemia * 1/206 (0.49%)   Leukopenia * 0/206 (0.00%)   Thrombocytopenia * 1/206 (0.49%)   Cardiac failure * 0/206 (0.00%)   Cardiac failure congestive * 1/206 (0.49%)   Cardiomyopathy * 0/206 (0.00%)   Coronary artery occlusion * 1/206 (0.49%)   Coronary artery thrombosis * 0/206 (0.00%) Adverse Events 2:   Total: 72/215 (33.49%)   Febrile neutropenia * 18/215 (8.37%)   Neutropenia * 6/215 (2.79%)   Anaemia * 1/215 (0.47%)   Leukopenia * 1/215 (0.47%)   Thrombocytopenia * 0/215 (0.00%)   Cardiac failure * 1/215 (0.47%)   Cardiac failure congestive * 0/215 (0.00%)   Cardiomyopathy * 1/215 (0.47%)   Coronary artery occlusion * 0/215 (0.00%)   Coronary artery thrombosis * 1/215 (0.47%)